NDC 0005-1971-05 Prevnar 13

Pneumococcal 13-valent Conjugate Vaccine

NDC Package Code 0005-1971-05

Field Name Field Value
NDC Code 0005-1971-05
Package Description 1 SYRINGE in 1 CARTON > .5 mL in 1 SYRINGE (0005-1971-01)
Proprietary Name Prevnar 13 Additional informationCallout TooltipWhat is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
Non-Proprietary Name Pneumococcal 13-valent Conjugate Vaccine Additional informationCallout TooltipWhat is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
11-Digit NDC Billing Format 00005197105 Additional informationCallout TooltipNDC Format for Billing
For insurance billing purposes the Centers for Medicare & Medicaid Services (CMS) created an 11 digit NDC derivative identifier. If the NDC Package code is less than 11 digits the code must be padded with leading zeros. The leading zeros must be added to the appropriate segment to create a 5-4-2 configuration.
Billing Unit ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
Product Type Vaccine Additional informationCallout TooltipWhat kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
Labeler Name Wyeth Pharmaceutical Division Of Wyeth Holdings Llc, A Subsidiary Of Pfizer Inc.
Dosage Form Injection, Suspension - A liquid preparation, suitable for injection, which consists of solid particles dispersed throughout a liquid phase in which the particles are not soluble. It can also consist of an oil phase dispersed throughout an aqueous phase, or vice-versa.
Administration Route(s)
  • Intramuscular - Administration within a muscle.
Active Ingredient(s)
  • STREPTOCOCCUS PNEUMONIAE TYPE 1 CAPSULAR POLYSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN 2.2 ug/.5mL
  • STREPTOCOCCUS PNEUMONIAE TYPE 3 CAPSULAR POLYSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN 2.2 ug/.5mL
  • STREPTOCOCCUS PNEUMONIAE TYPE 4 CAPSULAR POLYSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN 2.2 ug/.5mL
  • STREPTOCOCCUS PNEUMONIAE TYPE 5 CAPSULAR POLYSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN 2.2 ug/.5mL
  • STREPTOCOCCUS PNEUMONIAE TYPE 6A CAPSULAR POLYSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN 2.2 ug/.5mL
  • STREPTOCOCCUS PNEUMONIAE TYPE 6B CAPSULAR POLYSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN 4.4 ug/.5mL
  • STREPTOCOCCUS PNEUMONIAE TYPE 7F CAPSULAR POLYSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN 2.2 ug/.5mL
  • STREPTOCOCCUS PNEUMONIAE TYPE 9V CAPSULAR POLYSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN 2.2 ug/.5mL
  • STREPTOCOCCUS PNEUMONIAE TYPE 14 CAPSULAR POLYSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN 2.2 ug/.5mL
  • STREPTOCOCCUS PNEUMONIAE TYPE 18C CAPSULAR POLYSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN 2.2 ug/.5mL
  • STREPTOCOCCUS PNEUMONIAE TYPE 23F CAPSULAR POLYSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN 2.2 ug/.5mL
  • STREPTOCOCCUS PNEUMONIAE TYPE 19A CAPSULAR POLYSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN 2.2 ug/.5mL
  • STREPTOCOCCUS PNEUMONIAE TYPE 19F CAPSULAR POLYSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN 2.2 ug/.5mL
Pharmacological Class(es)
  • Inactivated Pneumococcal Vaccine - [EPC] (Established Pharmacologic Class)
  • Actively Acquired Immunity - [PE] (Physiologic Effect)
  • Vaccines -
  • Inactivated - [Chemical/Ingredient]
  • Pneumococcal Vaccines - [Chemical/Ingredient]
  • Inactivated Pneumococcal Vaccine - [EPC] (Established Pharmacologic Class)
  • Actively Acquired Immunity - [PE] (Physiologic Effect)
  • Vaccines -
  • Inactivated - [Chemical/Ingredient]
  • Pneumococcal Vaccines - [Chemical/Ingredient]
  • Inactivated Pneumococcal Vaccine - [EPC] (Established Pharmacologic Class)
  • Actively Acquired Immunity - [PE] (Physiologic Effect)
  • Vaccines -
  • Inactivated - [Chemical/Ingredient]
  • Pneumococcal Vaccines - [Chemical/Ingredient]
  • Inactivated Pneumococcal Vaccine - [EPC] (Established Pharmacologic Class)
  • Actively Acquired Immunity - [PE] (Physiologic Effect)
  • Vaccines -
  • Inactivated - [Chemical/Ingredient]
  • Pneumococcal Vaccines - [Chemical/Ingredient]
  • Inactivated Pneumococcal Vaccine - [EPC] (Established Pharmacologic Class)
  • Actively Acquired Immunity - [PE] (Physiologic Effect)
  • Vaccines -
  • Inactivated - [Chemical/Ingredient]
  • Pneumococcal Vaccines - [Chemical/Ingredient]
  • Inactivated Pneumococcal Vaccine - [EPC] (Established Pharmacologic Class)
  • Actively Acquired Immunity - [PE] (Physiologic Effect)
  • Vaccines -
  • Inactivated - [Chemical/Ingredient]
  • Pneumococcal Vaccines - [Chemical/Ingredient]
  • Inactivated Pneumococcal Vaccine - [EPC] (Established Pharmacologic Class)
  • Actively Acquired Immunity - [PE] (Physiologic Effect)
  • Vaccines -
  • Inactivated - [Chemical/Ingredient]
  • Pneumococcal Vaccines - [Chemical/Ingredient]
  • Inactivated Pneumococcal Vaccine - [EPC] (Established Pharmacologic Class)
  • Actively Acquired Immunity - [PE] (Physiologic Effect)
  • Pneumococcal Vaccines - [Chemical/Ingredient]
  • Vaccines -
  • Conjugate - [Chemical/Ingredient]
  • Inactivated Pneumococcal Vaccine - [EPC] (Established Pharmacologic Class)
  • Actively Acquired Immunity - [PE] (Physiologic Effect)
  • Vaccines -
  • Inactivated - [Chemical/Ingredient]
  • Pneumococcal Vaccines - [Chemical/Ingredient]
  • Inactivated Pneumococcal Vaccine - [EPC] (Established Pharmacologic Class)
  • Actively Acquired Immunity - [PE] (Physiologic Effect)
  • Vaccines -
  • Inactivated - [Chemical/Ingredient]
  • Pneumococcal Vaccines - [Chemical/Ingredient]
  • Inactivated Pneumococcal Vaccine - [EPC] (Established Pharmacologic Class)
  • Actively Acquired Immunity - [PE] (Physiologic Effect)
  • Vaccines -
  • Inactivated - [Chemical/Ingredient]
  • Pneumococcal Vaccines - [Chemical/Ingredient]
  • Inactivated Pneumococcal Vaccine - [EPC] (Established Pharmacologic Class)
  • Actively Acquired Immunity - [PE] (Physiologic Effect)
  • Vaccines -
  • Inactivated - [Chemical/Ingredient]
  • Pneumococcal Vaccines - [Chemical/Ingredient]
  • Inactivated Pneumococcal Vaccine - [EPC] (Established Pharmacologic Class)
  • Actively Acquired Immunity - [PE] (Physiologic Effect)
  • Vaccines -
  • Inactivated - [Chemical/Ingredient]
  • Pneumococcal Vaccines - [Chemical/Ingredient]
Marketing Category BLA - A product marketed under an approved Biologic License Application. Additional informationCallout TooltipWhat is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
FDA Application Number BLA125324 Additional informationCallout TooltipWhat is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Start Marketing Date 03-12-2010 Additional informationCallout TooltipWhat is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.

The NDC Code 0005-1971-05 is assigned to Prevnar 13, a vaccine lable labeled by Wyeth Pharmaceutical Division Of Wyeth Holdings Llc, A Subsidiary Of Pfizer Inc.. The product's dosage form is injection, suspension and is administered via intramuscular form.


Code Structure
  • 0005 - Wyeth Pharmaceutical Division Of Wyeth Holdings Llc, A Subsidiary Of Pfizer Inc.
    • 0005-1971 - Prevnar 13
      • 0005-1971-05 - 1 SYRINGE in 1 CARTON

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the disclaimer below.

NDC HCPCS Crosswalk

This crosswalk is intended to help the public understand which drug products (identified by NDCs) are assigned to which HCPCS billing codes.

NDC 0005-1971-05 HCPCS crosswalk information with package details and bill units information.

NDC Billing CodeHCPCS CodeHCPCS Code Desc.DosagePackage SizePackage QuantityBillable UnitsBillable Units / Pkg
0000519710590670PCV13 Vaccine IM0.5 ML0.5111

* Please review the disclaimer below.

Other Product Packages

The following packages are also available for Prevnar 13 with product NDC 0005-1971.

NDC Package CodePackage Description
0005-1971-0210 SYRINGE in 1 CARTON > .5 mL in 1 SYRINGE (0005-1971-01)

* Please review the disclaimer below.

Previous Code
0005-0100
Next Code
0005-2500